Tailored therapy of ACE inhibitors in stable coronary artery disease: Pharmacogenetic profiling of treatment benefit

Pharmacogenomics

Volumn 11, Issue 8, 2010, Pages 1115-1126

  Brugts, Jasper J ^a   Boersma, Eric ^a   Simoons, Maarten L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ACE inhibitors; coronary artery disease; gene; haplotype; perindopril; pharmacogenetics; polymorphism; secondary prevention

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KALLIKREIN; PERINDOPRIL; PLACEBO;

BLOOD PRESSURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART ARREST; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; PHARMACOGENETICS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STROKE; UNSTABLE ANGINA PECTORIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERY DISEASE; HAPLOTYPES; HUMANS; PERINDOPRIL; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME;

EID: 77955606337     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.103     Document Type: Review

References (47)

1. Pellacani A, Brunner HR, Nussberger J: Plasma kinins increase after angiotensin enzyme inhibition in human subjects. Clin. Sci. (Lond.) 87, 567-574 (1994).
2. Ferrari R: Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev. Cardiovasc. Ther. 3, 15-29 (2005).
3. Brugts JJ, den Uil CA, Danser AHJ, Boersma E: The renin-angiotensin- aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology 112, 303-312 (2009).
4. Overview of prior research in renin-angiotensin-aldosteron system genetics. Pfeffer MA, Braunwald E, SAVE Investigators et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the survival and ventricular enlargement trial. N. Engl. J. Med. 327, 669-677 (1992).
5. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
6. The Acute Infarction Ramipril Effcacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, 821-828 (1993).
7. Torp-Pedersen C, Kober L; TRACE Study Group: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 354, 9-12 (1999).
8. The Heart Outcomes Prevention Evaluation study investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
9. The PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351, 2058-2068 (2004).
10. The European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease Investigators: Effcacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 362, 782-788 (2003).
11. Main results of the European trial On Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery disease (EUROPA) trial.
12. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology: Guidelines on the management of stable angina pectoris. Eur. Heart J. 27, 1341-1381 (2006).
13. Wood D, DeBacker G, Faergam O, Graham I, Mancia G, Pyörälä K and the task force: Prevention of coronary disease in clinical practice: recommendation of the second Joint Task Force of European and other societies on Coronary Prevention. Atherosclerosis 140, 99-270 (1998).
14. Gibbons RJ, Abrams J, Chatterjee K et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J. Am. Coll. Cardiol. 41, 159-168 (2003). (Pubitemid 36044419)
15. Brugts JJ, Ferrari R, Simoons ML: Angiotesin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Exp. Rev. Cardiovasc. Ther. 7(4), 345-360 (2009).
16. Overview of the cardioprotective effects of perindopril across the broad range of vascular disease patients. Bots ML, Remme WJ, Lüscher TF et al.: ACE inhibition and endothelial function: main fndings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc. Drugs Ther. 21, 269-279 (2007).
17. Rodriguez-Granillo GA, Vos J, De Feyter PJ: Long-term effect of perindopril on coronary atherosclerosis progression (from the Perindopril's Prospective Effect on Coronary aThero sclero sis by Angiography and Intravascular Ultrasound Evaluation [PERSPECTIVE] Study). Am. J. Cardiol. 100, 159-163 (2007).
18. Ceconi C, Fox KM, Ferrari R et al.: ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 73, 237-246 (2007).
19. Remme WJ, Deckers JW, Fox KM, Ferrari R, Bertrand M, Simoons ML; for the EUROPA Investigators: Secondary prevention of coronary disease with ACE inhibition-does blood pressure reduction with perindopril explain the benefts in EUROPA? Cardiovasc. Drugs Ther. 23(2), 161-170 (2009)
20. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S: Angiotensin converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368, 581-588 (2006).
21. Consistent treatment beneft of perindopril in coronary artery disease patients. Deckers J W, Goedhart DM, Boersma E et al.: Treatment beneft by perindopril in patients with stable coronary artery disease at different levels of risk. Eur. Heart J. 27, 796-801 (2006).
22. Consistent treatment beneft of perindopril independent of patient's baseline risk of cardiovascular disease. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC: Renal function and risk of myocardial infarction in an elderly population: the Rotterdam study. Arch. Intern. Med. 165, 2659-2665 (2005).
23. Brugts JJ, Boersma E, Chonchol M et al.: The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modifed by mild to moderate renal insuffciency: insights from the EUROPA trial. J. Am. Coll. Cardiol. 50, 2148-2155 (2007).
24. Treatment beneft of perindopril independent of renal insuffciency. Brugts JJ, Ninomiya T, Boersma E et al.: The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur. Heart J. 30, 1385-1394 (2009).
25. Danser AHJ, Schunkert H: Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur. J. Pharmacol. 410, 303-316 (2000).
26. Brugts JJ, de Maat M, den Uil CA et al.: Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Curr. Opin. Cardiol. 23, 296-301 (2008).
27. Simon T, Verstuyft C, Mary-Kraue M et al.; for the FAST-MI Investigators: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
28. The SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy, a genome wide study. N. Engl. J. Med. 359, 789-799 (2008).
29. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
30. Tailored therapy of anticoagulants by pharmacogenetics becomes feasible. Arnett DK, Davis BR, Ford CE et al.: Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111, 3374-3383 (2005).
31. PROGRESS Collaborative Group: The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefts of ACE inhibition. Hypertension 42, 297-303 (2003).
32. Su X, Lee L, Li X et al.: Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 115, 725-732 (2007).
33. Brugts JJ, de Maat M, Boersma E et al.: The rationale and design of the Perindopril Genetic Association Study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 23, 171-181 (2009).
34. Study design of the Perindopril Genetic association (PERGENE) study.
35. van der Net JB, van Etten J, Yazdanpanah M et al.: Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia. Eur. Heart J. 29(11), 1370-1376 (2008).
36. Brugts JJ, Isaacs A, Boersma E et al.: Genetic determinants of treatment beneft of angiotensin-converting enzyme-inhibitor therapy in patients with stable coronary artery disease. Eur. Heart J. 31(15), 1854-1864 (2010).
37. Main results of PERGENE: pharmacogenetic profle of ACE-inhibitor treatment effect. Merino VF, Todiras M, Mori MA et al.: Predisposition to atherosclerosis and aortic aneurysms in mice defcient in kinin B1 receptor and apolipoprotein E. J. Mol. Med. 87(10), 953-963 (2009).
38. Luft FC: Aneurysm formation and bradykinin. J. Mol. Med. 87(10), 941-943 (2009).
39. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ: Effect of bradykinin-receptor blockade on the response to angiotensin converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. 339, 1285-1292 (1998).
40. 1 cardioprotective effect of ACE inhibitors and angiotensin receptor blockers. Exp. Physiol. 94(3), 322-329 (2009).
41. Marin-Castaño ME, Schanstra JP, Neau E et al.: Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 5, 627-632 (2002).
42. Ignatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos GE: Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of the bradykinin receptor type I. J. Biol. Chem. 277, 16847-16852 (2002).
43. Ignjatovic T, Stanisavljevic S, Brovkovych V, Skidgel RA, Erdos EG: Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol. Pharmacol. 66, 1310-1316 (2004).
44. Forten JP, Gobeil F Jr, Adam A, Regoli D, Marceau F: Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B receptor? Am. J. Physiol. Heart Circ. Physiol. 285, H277-H282 (2003).
45. Su JB, Hoüel R, Héloire F et al.: Stimulation of bradykinin B receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs. Circulation 101, 1848-1853 (2000).
46. Austinat M, Braeuninger S, Pesquero JB et al.: Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 40, 285-293 (2009).
47. Brugts JJ, Yetgin T, Hoeks S et al.: The beneft of HMG CoA reductase inhibitors in patients without established cardiovascular disease with cardiovascular risk factors. BMJ 338, b2376 (2009).